Interestingly, despite its weak activity on the BBB, RAP treatment with or without rt-PA resulted in a marked decrease in mortality within 24 h from stroke onset (from 71.4% overall mortality in vehicle and rt-PA groups to 21% in RAP-treated groups, p < 0.05, Fig. 3a). The gene discussed is LRPAP1; the disease is stroke disorder.